New drug-eluting stents: technological refinement continues

The arrival of drug-eluting stents (DES) nearly 2 decades ago ignited a revolution in the field of interventional cardiology. The addition of antiproliferative drugs to the stent platform reduced the rate of in-stent restenosis significantly and increased the number of patients that, to this date, h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Javier Suárez de Lezo, Pedro Martín
Formato:	article
Lenguaje:	EN ES
Publicado:	Permanyer 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/626637bdb4554f3cbe5e3a267662bc8a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:626637bdb4554f3cbe5e3a267662bc8a
record_format	dspace
spelling	oai:doaj.org-article:626637bdb4554f3cbe5e3a267662bc8a2021-11-16T10:24:10ZNew drug-eluting stents: technological refinement continues10.24875/RECICE.M210002302604-7322https://doaj.org/article/626637bdb4554f3cbe5e3a267662bc8a2021-11-01T00:00:00Zhttps://recintervcardiol.org/en/index.php?option=com_content&view=article&id=722https://doaj.org/toc/2604-7322The arrival of drug-eluting stents (DES) nearly 2 decades ago ignited a revolution in the field of interventional cardiology. The addition of antiproliferative drugs to the stent platform reduced the rate of in-stent restenosis significantly and increased the number of patients that, to this date, have benefited from percutaneous revascularization.1,2 However, its Achilles tendon was initially the higher rate of late stent thrombosis involved. The permanent polymer used in the first generation of DES induced inflammatory and hypersensitivity reactions that delayed endothelization. A health alert followed3 that made the medical community recommend extended courses of dual antiplatelet therapy and put into question the convenience of DES. Beyond the increased rate of stent thrombosis, the first-generation of this type of stents had additional limitations: they were stainless-steel platforms with up to 140 µm thick struts, worse stent navigability, and fewer crossing capabilities. Also, the stent maximum expansion was limited (3.5 mm in the Cypher stent, Cordis Corp.), which occasionally prevented treating left main coronary artery lesions. With the passing of time, this stent technology has been refined to a point that there has been a major overhaul in its 3 main components: platform, polymer, and antiproliferative drug. The changes made to the...Javier Suárez de LezoPedro MartínPermanyerarticleMedicineRENESREC: Interventional Cardiology (English Ed.), Vol 3, Iss 4, Pp 247-249 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	Medicine R
spellingShingle	Medicine R Javier Suárez de Lezo Pedro Martín New drug-eluting stents: technological refinement continues
description	The arrival of drug-eluting stents (DES) nearly 2 decades ago ignited a revolution in the field of interventional cardiology. The addition of antiproliferative drugs to the stent platform reduced the rate of in-stent restenosis significantly and increased the number of patients that, to this date, have benefited from percutaneous revascularization.1,2 However, its Achilles tendon was initially the higher rate of late stent thrombosis involved. The permanent polymer used in the first generation of DES induced inflammatory and hypersensitivity reactions that delayed endothelization. A health alert followed3 that made the medical community recommend extended courses of dual antiplatelet therapy and put into question the convenience of DES. Beyond the increased rate of stent thrombosis, the first-generation of this type of stents had additional limitations: they were stainless-steel platforms with up to 140 µm thick struts, worse stent navigability, and fewer crossing capabilities. Also, the stent maximum expansion was limited (3.5 mm in the Cypher stent, Cordis Corp.), which occasionally prevented treating left main coronary artery lesions. With the passing of time, this stent technology has been refined to a point that there has been a major overhaul in its 3 main components: platform, polymer, and antiproliferative drug. The changes made to the...
format	article
author	Javier Suárez de Lezo Pedro Martín
author_facet	Javier Suárez de Lezo Pedro Martín
author_sort	Javier Suárez de Lezo
title	New drug-eluting stents: technological refinement continues
title_short	New drug-eluting stents: technological refinement continues
title_full	New drug-eluting stents: technological refinement continues
title_fullStr	New drug-eluting stents: technological refinement continues
title_full_unstemmed	New drug-eluting stents: technological refinement continues
title_sort	new drug-eluting stents: technological refinement continues
publisher	Permanyer
publishDate	2021
url	https://doaj.org/article/626637bdb4554f3cbe5e3a267662bc8a
work_keys_str_mv	AT javiersuarezdelezo newdrugelutingstentstechnologicalrefinementcontinues AT pedromartin newdrugelutingstentstechnologicalrefinementcontinues
_version_	1718426551215718400

New drug-eluting stents: technological refinement continues

Ejemplares similares